| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87481 |
|
3,656 |
3,016 |
$473K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
9,505 |
3,106 |
$452K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
895 |
833 |
$434K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,369 |
2,811 |
$244K |
| 87581 |
|
4,125 |
3,468 |
$146K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
3,874 |
3,215 |
$136K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,980 |
2,443 |
$135K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
8,415 |
2,656 |
$129K |
| 87500 |
|
4,847 |
3,951 |
$125K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
7,350 |
6,027 |
$109K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
1,176 |
963 |
$109K |
| 87653 |
|
3,022 |
2,515 |
$108K |
| 87541 |
|
2,961 |
2,461 |
$105K |
| 84443 |
Thyroid stimulating hormone (TSH) |
6,511 |
5,498 |
$90K |
| 82607 |
|
6,737 |
5,488 |
$73K |
| 80053 |
Comprehensive metabolic panel |
7,593 |
6,061 |
$59K |
| 80061 |
Lipid panel |
8,137 |
6,785 |
$56K |
| 82746 |
|
4,698 |
3,666 |
$47K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
6,974 |
5,971 |
$42K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,969 |
6,637 |
$41K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,215 |
1,095 |
$37K |
| 86141 |
|
2,845 |
2,235 |
$36K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
751 |
666 |
$31K |
| 87641 |
|
826 |
710 |
$28K |
| 82728 |
|
3,672 |
2,900 |
$27K |
| 87486 |
|
695 |
662 |
$27K |
| 84439 |
|
3,425 |
2,712 |
$26K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
993 |
843 |
$24K |
| 87640 |
|
643 |
564 |
$24K |
| 83540 |
|
3,445 |
2,841 |
$18K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
496 |
439 |
$18K |
| 87634 |
|
341 |
326 |
$17K |
| 87400 |
|
1,040 |
497 |
$16K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
532 |
505 |
$16K |
| 87498 |
|
388 |
339 |
$15K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
775 |
375 |
$14K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
388 |
375 |
$14K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
403 |
335 |
$14K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
403 |
335 |
$14K |
| 81514 |
|
80 |
62 |
$13K |
| 87563 |
|
736 |
610 |
$12K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,495 |
1,426 |
$12K |
| 84153 |
|
795 |
668 |
$10K |
| 36415 |
Collection of venous blood by venipuncture |
3,181 |
2,810 |
$9K |
| 86480 |
|
200 |
154 |
$9K |
| 83550 |
|
1,355 |
1,196 |
$9K |
| 87999 |
|
78 |
62 |
$9K |
| 83735 |
|
1,507 |
1,371 |
$8K |
| 80076 |
|
903 |
884 |
$8K |
| 86706 |
|
638 |
524 |
$7K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
129 |
122 |
$7K |
| 84480 |
|
794 |
736 |
$6K |
| 86735 |
|
528 |
424 |
$6K |
| 83880 |
|
188 |
156 |
$5K |
| 80074 |
|
112 |
108 |
$5K |
| 84436 |
|
1,015 |
923 |
$5K |
| 82570 |
|
1,131 |
955 |
$4K |
| 86762 |
|
532 |
434 |
$4K |
| 85027 |
|
954 |
859 |
$4K |
| 82043 |
|
1,158 |
954 |
$4K |
| 86765 |
|
520 |
424 |
$4K |
| 86592 |
|
1,055 |
900 |
$4K |
| 86038 |
|
261 |
241 |
$3K |
| 83519 |
|
263 |
195 |
$3K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
26 |
24 |
$3K |
| 87800 |
|
103 |
76 |
$3K |
| 81003 |
|
1,439 |
1,323 |
$2K |
| 87631 |
|
26 |
26 |
$2K |
| 86803 |
|
180 |
157 |
$2K |
| 86200 |
|
156 |
145 |
$2K |
| 83001 |
|
121 |
92 |
$2K |
| 84403 |
|
74 |
57 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
194 |
183 |
$2K |
| 86431 |
|
247 |
232 |
$1K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
66 |
62 |
$1K |
| 83002 |
|
105 |
77 |
$1K |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
57 |
49 |
$1K |
| 82378 |
|
62 |
60 |
$1K |
| 84702 |
|
110 |
99 |
$1K |
| 85652 |
|
408 |
358 |
$988.82 |
| 84481 |
|
95 |
73 |
$968.32 |
| 84156 |
|
410 |
295 |
$889.61 |
| 84550 |
|
265 |
234 |
$847.77 |
| 84479 |
|
117 |
110 |
$531.02 |
| 82172 |
|
45 |
42 |
$525.87 |
| 85610 |
|
140 |
98 |
$463.76 |
| 84146 |
|
34 |
25 |
$410.19 |
| 86304 |
|
19 |
17 |
$406.90 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
15 |
14 |
$198.64 |
| 83655 |
|
14 |
14 |
$148.24 |
| 84703 |
|
27 |
25 |
$142.15 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
18 |
16 |
$127.58 |
| 83090 |
|
14 |
14 |
$123.22 |
| 83721 |
|
16 |
15 |
$102.56 |
| 85730 |
|
31 |
26 |
$97.24 |
| 83695 |
|
14 |
14 |
$76.01 |
| 80050 |
General health panel |
12 |
12 |
$12.93 |